Aethlon Medical, Inc. (AEMD)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.28-0.02 (-0.38%)
As of 11:17 AM EDT. Market open.
People also watch:
CTSOAMARADXSBKYIIBIO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5.26
Prev Close5.30
Bid5.22 x 100
Ask5.27 x 200
Day's Range5.20 - 5.32
52wk Range4.02 - 9.09
1y Target EstN/A
Market Cap40.29M
P/E Ratio (ttm)-6.91
Beta2.01
Volume11,168
Avg Vol (3m)46,812
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of AEMD earnings conference call or presentation 11-Aug-16 8:30pm GMT

    Q1 2017 Aethlon Medical Inc Earnings Call

  • Zacks Small Cap Research11 days ago

    AEMD: Q1 Results. Add Zika to List of Potential Targets

    Aethlon (AEMD) reported financial results for their first quarter 2017 and provided and operational update.  Financial results were largely inline with our expectations although there was a notable positive variance in operating expenses, reflecting a combination of management's continued diligence on expense control as well as lower than anticipated spend on R&D - the latter which we attribute to slower trajectory to the U.S. feasibility study as compared to what we had been modeling.  But the study is now 50% enrolled and management is still guiding for completion by current year-end. Revenue was just $5k in the quarter - inline with what we had expected, and entirely related to the Battelle subcontract.  AEMD still has almost $400k under the DARPA contract yet to be billed, at least a portion of which we think could be booked in the current quarter (i.e.

  • PR Newswire18 days ago

    Aethlon Medical Announces Fiscal 2017 First Quarter Results

    SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal ...